Search Result

Pathways Recommended:	NF-κB

Results for "

NFκB

" in MedChemExpress (MCE) Product Catalog:

By Targets:	NF-κB (584) 5-HT Receptor (2) Acyltransferase (12) Adenosine Receptor (6) Adrenergic Receptor (7) AIM2 (2) Akt (35) AMPK (6) Amylases (2) Amyloid-β (9) Androgen Receptor (1) Angiotensin Receptor (1) Angiotensin-converting Enzyme (ACE) (6) Antibiotic (15) AP-1 (6) Apoptosis (184) Aryl Hydrocarbon Receptor (1) Autophagy (66) Bacterial (53) Bcl-2 Family (10) Beta-secretase (1) Biochemical Assay Reagents (1) Btk (1) c-Met/HGFR (1) c-Myc (3) Calcium Channel (10) Carbonic Anhydrase (1) Caspase (17) CCR (2) CDK (7) Chloride Channel (2) Cholinesterase (ChE) (1) COX (74) CXCR (3) Cyclin G-associated Kinase (GAK) (1) Cytochrome P450 (2) Dengue virus (1) Deubiquitinase (1) DNA/RNA Synthesis (4) Dopamine Receptor (2) E1/E2/E3 Enzyme (9) EGFR (2) Elastase (1) Endogenous Metabolite (76) Epigenetic Reader Domain (5) ERK (41) Estrogen Receptor/ERR (5) Eukaryotic Initiation Factor (eIF) (3) Factor Xa (2) FAK (2) Ferroptosis (16) FGFR (1) Flavivirus (1) FOXO (1) Fungal (13) Glucocorticoid Receptor (5) GLUT (6) Glutathione S-transferase (4) HBV (1) HCV (1) HDAC (10) HIF/HIF Prolyl-Hydroxylase (5) Histone Acetyltransferase (3) Histone Demethylase (2) Histone Methyltransferase (1) HIV (16) HSP (4) HSV (4) IAP (3) IGF-1R (2) IKK (28) Influenza Virus (12) Insulin Receptor (2) Interleukin Related (45) IRAK (6) Isotope-Labeled Compounds (24) JAK (12) JNK (24) Keap1-Nrf2 (28) Leukotriene Receptor (5) Lipoxygenase (3) MALT1 (2) MAP3K (1) MAP4K (1) MAPKAPK2 (MK2) (1) MDM-2/p53 (4) MEK (11) Melanocortin Receptor (1) mGluR (3) Microtubule/Tubulin (4) Mineralocorticoid Receptor (1) Mitochondrial Metabolism (6) Mitophagy (18) MMP (17) Molecular Glues (2) Monoamine Oxidase (1) mTOR (6) MyD88 (6) Na+/K+ ATPase (3) nAChR (3) Necroptosis (1) NO Synthase (41) NOD-like Receptor (NLR) (13) Nuclear Factor of activated T Cells (NFAT) (2) Opioid Receptor (4) Organoid (2) Oxidative Phosphorylation (3) P-glycoprotein (5) P2Y Receptor (2) p38 MAPK (54) PAK (9) Parasite (24) PARP (1) PERK (2) PGC-1α (4) PGE synthase (4) Phosphatase (3) Phosphodiesterase (PDE) (9) PI3K (9) PKA (2) PKC (4) Potassium Channel (4) PPAR (22) Progesterone Receptor (3) PROTACs (5) Protease Activated Receptor (PAR) (1) Proteasome (16) PTEN (1) Pyroptosis (3) Pyruvate Kinase (2) RANKL/RANK (5) Ras (1) Reactive Oxygen Species (30) Ribosomal S6 Kinase (RSK) (2) RIP kinase (3) ROR (1) SARS-CoV (5) Ser/Thr Protease (2) Sirtuin (9) Sodium Channel (16) SphK (1) STAT (25) STING (5) Survivin (1) TGF-beta/Smad (2) TGF-β Receptor (1) TNF Receptor (69) Toll-like Receptor (TLR) (32) Topoisomerase (3) TrxR (1) Tyrosinase (7) VEGFR (5) Virus Protease (7) Wnt (3) β-catenin (1)
By Research Areas:	Cancer (413) Cardiovascular Disease (82) Endocrinology (21) Infection (109) Inflammation/Immunology (576) Metabolic Disease (60) Neurological Disease (84)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	CpG ODNs (2) Emulsifiers (1)

846

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

420

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

NF-κB-IN-11	NF-κB	Inflammation/Immunology
NF-κB-IN-11 (Compound 3i) is a *NF-κB* inhibitor. NF-κB-IN-11 inhibits TNF-α induced activation of NF-κB pathway, and inhibits nuclear translocation of NF-κB. NF-κB-IN-11 down-regulates the expression levels of phosphor-IKK, IκBα, and NF-κB p65. NF-κB-IN-11 has anti-inflammatory activity, and alleviates dextran sulfate sodium-induced colitis in mice. NF-κB-IN-11 (p.o.) shows a MTD more than 1852 mg/kg in mice acute toxicity assay .

NF-κB-IN-1 2 Publications Verification	IKK	Cancer
NF-κB-IN-1, a 4-arylidene crucumin analogue, is a potent NF-κB signaling pathway inhibitor. NF-κB-IN-1 directly inhibits IKK to block NF-κB activation. NF-κB-IN-1 effectively inhibits the viability of lung cancer cells and attenuates the clonogenic activity of A549 cells .

NF-κB-IN-4	NF-κB Apoptosis	Neurological Disease Inflammation/Immunology
NF-κB-IN-4 (compound 17) is a potent and BBB-penetrated *NF-κB* pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research .

NF-κB-IN-17	NF-κB	Inflammation/Immunology
NF-κB-IN-17 (Zinc5) is a *NF-κB* inhibitor. NF-κB-IN-17 inhibits TNF-α-induced NF-κB DNA binding activity in C2C12 cells .

NF-κB-IN-9	NF-κB	Cancer
NF-κB-IN-9 is a nuclear factor kappa B (NF-κB) targeting sonosensitizer (λex/λem=489/628 nm). NF-κB-IN-9 exhibits strong inhibition on NF-κB signaling due to its two resveratrol units in one molecule. NF-κB-IN-9 has anti-tumor activity and shows remarkable sonocytotoxicity against cancer cells. NF-κB-IN-9 has biosafety in eenograft mice model.

NF-κB-IN-3	NF-κB	Cancer
NF-κB-IN-3 (Compound 2) is a *NF-κB* inhibitor with an IC₅₀ of 0.70 µM. NF-κB-IN-3 can be used as an antitumor agent .

NF-κB-IN-12	NF-κB	Inflammation/Immunology
NF-κB-IN-12 (compound 3h) is a potent *NF-κB* inhibitor, with an IC₅₀ of 1.02 μM. NF-κB-IN-12 can be used for acute lung injury research .

NF-κB-IN-10	NF-κB	Cardiovascular Disease
NF-κB-IN-10 (compound E1) is an *NF-κB* inhibitor that can improve heart failure by reducing oxidative stress and inflammation by regulating *Nrf2/NF-κB* signaling pathway. NF-κB-IN-10 inhibits LPS-induced NO production and expression of iNOS and COX-2 in RAW264.7 cells. NF-κB-IN-10 can be used in the research of cardiovascular diseases .

NF-κB-IN-13	NF-κB	Inflammation/Immunology
NF-κB-IN-13 (compound 12) can significantly inhibit LPS-induced *NF-κB* activation and NO production in RAW264.7 macrophages. NF-κB-IN-13 has anti-inflammatory effects .

NF-κB-IN-15	NF-κB	Inflammation/Immunology
NF-κB-IN-15 (compound 14r) is a potent *NF-κB* inhibitor. NF-κB-IN-15 decreases the NO levels and inhibits the release of IL-6, TNF-α, and IL-1β in LPS (HY-D1056) -induced cells. NF-κB-IN-15 inhibits LPS-induced phosphorylation of p65 and degradation of IκBα. NF-κB-IN-15 shows anti-inflammatory activity has the potential for the research of acute lung injury (ALI) .

NF-κB-IN-8	NF-κB	Inflammation/Immunology
NF-κB-IN-8 competitively antagonizes LPS binding to MD-2. NF-κB-IN-8 reduces the expression of inflammatory factors by binding to MD-2. NF-κB-IN-8 also inhibits ALP activity. NF-κB-IN-8 can be used for the research of inflammation such as acute lung injury (ALI) .

NF-κB-IN-2	NF-κB	Neurological Disease
NF-κB-IN-2 inhibits TNF-α-induced canonical NF-κB signaling in PC-3 cells.

NF-κB-IN-14	NF-κB Toll-like Receptor (TLR)	Inflammation/Immunology
NF-κB-IN-14 (compound 5e) significantly inhibits nitric oxide production in LPS-induced macrophages (IC₅₀: 6.4 μM). NF-κB-IN-14 disrupts the TLR4-MyD88 protein interaction, leading to the suppression of the *NF-κB* signaling pathway suppression. NF-κB-IN-14 reduces ear edema and inflammation in an atopic dermatitis mouse model .

NF-κB-IN-16	NF-κB Apoptosis	Cancer
NF-κB-IN-16 (compound 9) is a complex (Pt(IV) complex) of *NF-κB* inhibitor and Cisplatin (HY-17394), which has high efficacy and low toxicity in anti-tumor activity. active. NF-κB-IN-16 can cause DNA damage, induce mitochondrial dysfunction, produce reactive oxygen species, and induce apoptosis through the mitochondrial pathway and endoplasmic reticulum stress. NF-κB-IN-16 potently inhibits the NF-κB/MAPK signaling pathway and disrupts PI3K/AKT signaling. NF-κB-IN-16 also exhibits excellent in vivo antitumor efficiency and low toxicity in A549 or A549/CDDP xenograft models .

NF-κB/MAPK-IN-1	NF-κB p38 MAPK NO Synthase COX	Inflammation/Immunology
NF-κB/MAPK-IN-1 (compound 11a) is a potent inhibitor of *NF-κB* and MAPK pathway. NF-κB/MAPK-IN-1 shows inhibitory activity against NO production, with an IC₅₀ of 6.96 µM. NF-κB/MAPK-IN-1 suppresses LPS-induced iNOS, COX-2, ERΚ and P38 signaling activation. NF-κB/MAPK-IN-1 can prevent LPS induced inflammatory response in macrophages. NF-κB/MAPK-IN-1 can be used for rheumatoid arthritis (RA) research .

NF-κB-IN-5	NF-κB Apoptosis	Cancer
NF-κB-IN-5 (compound 4d) is an orally active and potent *NF-κB* inhibitor by interacting directly with NF-κB. NF-κB-IN-5 shows antitumor activity against human cancer cell lines (HCT116, U87-MG, HepG2, BGC823, PC9), with IC₅₀ values of 5.35, 2.81, 2.83, 2.02 and 3.90 μM, respectively. NF-κB-IN-5 induces apoptosis in U87-MG tumor cell and cell cycle arrest in G0/G1 phase .

NF-κB-IN-6	NF-κB	Inflammation/Immunology
NF-κB-IN-6 (Compound 3d) is an anti-inflammatory agent through the mechanism of decreasing the protein expressions of iNOS and COX-2 by suppressing *NF-κB* signaling pathway. NF-κB-IN-6 inhibits NO production in LPS-induced RAW264.7 cells with an IC₅₀ of 23.1 μM .

NF-κB/PON1-IN-1	NF-κB Reactive Oxygen Species	Cancer
NF-κB/PON1-IN-1 (Compound 16) is a *NF-κB/PON1* pathway inhibitor. NF-κB/PON1-IN-1 has antioxidant (IC₅₀ = 45.76 µM) and hepatoprotective activities .

Akt/NF-κB/JNK-IN-1	Akt NF-κB JNK TNF Receptor COX	Inflammation/Immunology
Akt/NF-κB/JNK-IN-1 (Compound 2i) is an inhibitor of Akt, *NF-κB* and JNK signaling pathways. Akt/NF-κB/JNK-IN-1 inhibits nitric oxide production with an IC₅₀ of 3.15 μM. Akt/NF-κB/JNK-IN-1 shows anti-inflammatory activities .

Glucocorticoid receptor/NF-κB modulator-1	Glucocorticoid Receptor NF-κB	Inflammation/Immunology
Glucocorticoid receptor/NF-κB modulator-1 (Compound 20) is a derivative of ocotillol. Glucocorticoid receptor/NF-κB modulator-1 suppresses the degradation of glucocorticoid receptor (GR) mRNA and GR protein, inhibits the activation of NF-κB signaling pathway. Glucocorticoid receptor/NF-κB modulator-1 downregulates levels of NO, interleukin-6 and tumor necrosis factor-alpha (TNF-α). Glucocorticoid receptor/NF-κB modulator-1 ameliorates sepsis in mouse model .

Akt/NF-κB/MAPK-IN-1	p38 MAPK ERK JNK Interleukin Related TNF Receptor NO Synthase COX	Others
Akt/NF-κB/MAPK-IN-1 (compound 2m) is a potent and orally active inhibitor against NO (IC₅₀=7.70 μM) with no significant toxicity. Akt/NF-κB/MAPK-IN-1 shows anti-inflammatory activity by inhibiting Akt/NF-κB and MAPK signaling pathways .

TLR4/NF-κB/MAPK-IN-1	NF-κB p38 MAPK Toll-like Receptor (TLR)	Neurological Disease Inflammation/Immunology
TLR4/NF-κB/MAPK-IN-1 is a new type of antineuroinflammatory agent by suppressing TLR4/NF-kB/MAPK pathways.

AP-1/NF-κB activation inhibitor 1 1 Publications Verification	NF-κB	Inflammation/Immunology
AP-1/NF-κB activation inhibitor 1 is a potent AP-1 and *NF-κB* mediated transcriptional activation inhibitor (IC₅₀=1 μM), without blocking basal transcription driven by the β-actin promoter. AP-1/NF-κB activation inhibitor 1 has a similar inhibitory effect on the production of IL-2 and IL-8 levels in stimulated cells .

Aconine 2 Publications Verification Jesaconine	NF-κB	Inflammation/Immunology Cancer
Aconine inhibits receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced *NF-κB* activation.

WAY-204688 SIM-688	NF-κB	Inflammation/Immunology
WAY-204688 is an estrogen receptor (ER-α) selective, orally active inhibitor of *NF-κB* transcriptional activity with an IC₅₀ of 122 ± 30 nM for NF-κB-luciferase (NF-κB-luc) in HAECT-1 cells.

JSH-23 90+ Cited Publications	NF-κB	Metabolic Disease Inflammation/Immunology Cancer
JSH-23 is an *NF-κB* inhibitor which inhibits NF-κB transcriptional activity with an IC₅₀ of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation .

PTD-p65-P1 Peptide TFA 3 Publications Verification	NF-κB Apoptosis	Inflammation/Immunology Cancer
PTD-p65-P1 Peptide TFA is a potent, selective nuclear transcription factor *NF-κB* inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis .

PTD-p65-P1 Peptide	NF-κB Apoptosis	Inflammation/Immunology Cancer
PTD-p65-P1 Peptide is a potent, selective nuclear transcription factor *NF-κB* inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis .

SEMBL	NF-κB MMP	Inflammation/Immunology Cancer
SEMBL is a potent *NF-κB* inhibitor. SEMBL can inhibit NF-κB-DNA binding, and also inhibits NF-κB-dependent inflammatory cytokine secretions. SEMBL inhibits cancer cell migration and invasion via decreasing MMP expression. SEMBL can be used for researching anticancer .

Multi-target Pt	NF-κB IKK	Cancer
Multi-target Pt (IV), an antitumor agent, suppresses the IKKβ phosphorylation, IκBα phosphorylation and NF-κB p65 phosphorylation and nuclear translocation, leading to blocked the NF-kB signal pathway .

SR12343	NF-κB IKK	Neurological Disease Inflammation/Immunology
SR12343, an *IKK/NF-κB* inhibitor, is a NF-κB essential modulator (NEMO)-binding domain (NBD) mimetic. SR12343 inhibits TNF-α- and LPS-induced NF-κB activation by blocking the interaction between IKKβ and NEMO, with an IC₅₀ of 37.02 μM for TNF-α-mediated NF-κB activation. SR12343 suppresses LPS-induced acute pulmonary inflammation in mice. SR12343 can be used for research of inflammatory and degenerative diseases .

Avenanthramide-C methyl ester	NF-κB	Inflammation/Immunology
Avenanthramide-C methyl ester is an anti-inflammatory agent and NF-κB inhibitor that inhibits the secretion of pro-inflammatory factors. Avenanthramide-C methyl ester inhibits NF-κB activation by inhibiting IKK and IκB phosphorylation and inhibiting proteasome activity .

Flaconitine Acetylaconitine; 3-Acetylaconitine	NF-κB	Neurological Disease Cancer
Flaconitine is considered to be a *NF-κB* inhibitor.

Caffeic acid phenethyl ester 10+ Cited Publications	NF-κB Apoptosis	Inflammation/Immunology Cancer
Caffeic acid phenethyl ester is a *NF-κB* inhibitor.

HSR1304	NF-κB	Cancer
HSR1304 (Compound 5d) is a potent inhibitor of NFκB. The multifunctional transcription factor, nuclear factor-κB (NF-κB), is broadly involved in multiple human diseases, such as cancer and chronic inflammation. HSR1304 has the potential for the research of cancer diseases .

(-)-DHMEQ 25+ Cited Publications Dehydroxymethylepoxyquinomicin	NF-κB	Inflammation/Immunology Cancer
(-)-DHMEQ (Dehydroxymethylepoxyquinomicin) is a potent, selective and irreversible *NF-κB* inhibitor that covalently binds to a cysteine residue. (-)-DHMEQ inhibits nuclear translocation of *NF-κB* and shows anti-inflammatory and anticancer activity .

Andrographolide 15+ Cited Publications Andrographis	NF-κB SARS-CoV Influenza Virus Autophagy Parasite	Infection Inflammation/Immunology Cancer
Andrographolide is a *NF-κB* inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.

SN50 30+ Cited Publications	NF-κB	Inflammation/Immunology
SN50 is a cell permeable inhibitor of *NF-κB* translocation.

IMD-vanillin	NF-κB	Cancer
IMD-vanillin is a novel imidazoquinolinone-NF-κB immunomodulator dimers.

BAY 11-7085 30+ Cited Publications BAY 11-7083	NF-κB Ferroptosis Apoptosis	Cancer
BAY 11-7085 (BAY 11-7083) is an inhibitor of *NF-κB* activation and phosphorylation of IκBα; it stabilizes IκBα with an IC₅₀ of 10 μM .

Schisantherin A 1 Publications Verification Gomisin-C; Schizantherin-A; Wuweizi ester-A	NF-κB	Inflammation/Immunology
Schisantherin A is a dibenzocyclooctadiene lignan. Schisantherin A inhibits *p65-NF-κB* translocation into the nucleus by IκBα degradation.

Cucurbitacin IIb 1 Publications Verification	Apoptosis	Inflammation/Immunology
Cucurbitacin IIb is an active component isolated from Hemsleya amabilis, induces apoptosis with anti-inflammatory activity. Cucurbitacin IIb inhibits phosphorylation of STAT3, JNK and Erk1/2, enhances the phosphorylation of IκB and NF-κB (p65), blocks nuclear translocation of NF-κB (p65) and decreases mRNA levels of IκBα and TNF-α .

Berbamine dihydrochloride 5+ Cited Publications	NF-κB Autophagy Apoptosis	Cancer
Berbamine dihydrochloride is an inhibitor of *NF-κB* activity with remarkable anti-myeloma efficacy.

DHMEQ racemate rel-DHMEQ	NF-κB	Cancer
DHMEQ racemate is a *NF-κB* inhibitor. DHMEQ racemate is less active than (-)-DHMEQ.

Edasalonexent CAT-1004	NF-κB	Metabolic Disease
Edasalonexent (CAT-1004) is an orally bioavailable *NF-κB* inhibitor.

IMD-0354 15+ Cited Publications IKK2 Inhibitor V	IKK	Cancer
IMD-0354 (IKK2 Inhibitor V) is a selective IKKβ inhibitor which inhibits NF-κB activity . IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC₅₀ of 1.2 uM .

Cat. No.	Product Name

HY-L014

NF-κB Signaling Compound Library

889 compounds

Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.

MCE owns a unique collection of 889 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

HY-L172

Immunopotentiator Compound Library

94 compounds

Immunity refers to the ability of the body to resist the invasion of pathogenic microorganisms and resist a variety of diseases. Immunocompromised will inevitably lead to a series of diseases. Immunopotentiator are a class of compounds that enhance immune function and induce immune response. Immunopotentiator can activate the proliferation and differentiation of one or more kinds of immune active cells in the body, promote the secretion of lymphocytes, and then enhance the immune function of the body. Immunopotentiator are mainly used in the treatment of tumors, infectious diseases and immunodeficiency diseases. In addition, immunopotentiator are often used as adjuvants in combination with vaccine antigens to enhance the immunogenicity of vaccines.

MCE designs a unique collection of 94 compounds with definite or potential Immunopotentiating effect, mainly targeting the NOD-like Receptor (NLR), Toll-like Receptor (TLR), NF-κB, etc. It is an effective tool for development and research of anti-cancer, anti-infectious diseases and anti-immunodeficiency diseases compounds.

HY-L037

Antioxidant Compound Library

1,632 compounds

Oxidative stress is an imbalance of free radicals and antioxidants in the body, which can lead to cell and tissue damage. Oxidative stress can be responsible for the induction of several diseases, both chronic and degenerative, as well as speeding up body aging process and cause acute pathologies. Antioxidants are a class of compounds able to counteract oxidative stress and mitigate its effects on individuals’ health, gained enormous attention from the biomedical research community. Antioxidants have long been substantial and amenable therapeutic arsenals for multifarious diseases such as AD and cancer.

MCE Antioxidant Compound Library contains 1,632 compounds that act as antioxidants for high throughput screening (HTS) and high content screening (HCS). This library is a useful tool for discovery new antioxidants and oxidative stress research.

HY-L090

Transcription Factor-Targeted Library

1,443 compounds

Transcription is the essential first step in the conversion of the genetic information in the DNA into protein and the major point at which gene expression is controlled. Transcription of protein-coding genes is accomplished by the multi-subunit enzyme RNA polymerase II and an ensemble of ancillary proteins, called transcription factors (TFs). Transcription factors play an important role in the long-term regulation of cell growth, differentiation and responses to environmental cues. Deregulated transcription factors contribute to the pathogenesis of a plethora of human diseases, ranging from diabetes, inflammatory disorders and cardiovascular disease to many cancers, and thus these proteins hold great therapeutic potential.

MCE offers a unique collection of 1,443 compounds with validated transcription factor targets modulating properties. MCE transcription factor-targeted compound library is an effective tool for researching transcription factors as drug targets as well as modulation of TFs for different therapeutic applications.

HY-L199

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

3,225 compounds

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 3,225 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

HY-L201

Cell Proliferation Compound Library

2,161 compounds

Cell proliferation, the increase in cell numbers resulting from cell division, is a complex and tightly regulated process. Cell proliferation is regulated by coordinated entry into the cell cycle, and changes in proliferation are closely linked to disease development. Evolutionary dynamics links tumor growth and progression with cell proliferation, cell death, and mutation rates. In addition, cell proliferation is central to degenerative diseases, the development of which is often accompanied by accelerated multiplication of cancer cells. Therefore, assays of cell proliferation levels are frequently used for laboratory research purposes and increasingly for clinical assessment of tumor aggressiveness and potentially to guide care. It has been shown that multiple key targets are collectively involved in regulating the process of cell proliferation, such as CDK, E2F, pRB, β-Catenin, and others.

MCE collects 2,161 compounds that target and regulate key targets of cell proliferation, which can be used in studies of cell proliferation mechanisms and drug discovery.

HY-L124

Anti-Prostate Cancer Compound Library

2,449 compounds

Cancer is one of the leading causes of mortality amongst world’s population, in which prostate cancer (PCa) is one of the most encountered malignancies among men. Several molecular mechanisms are involved in prostate cancer development and progression. These include common survival factors in prostate cancer (IGF-1), growth factors (TGF-α, EGF), Wnt, Hedgehog, NF-κB, and mTOR and other signaling pathways. These provide potential therapeutic target in prostate cancer treatment.

MCE offers a unique collection of 2,449 compounds with identified and potential anti-prostate cancer activity. MCE Anti-Prostate Cancer Compound Library is a useful tool for anti-prostate cancer drugs screening and other related research.

HY-L103

Anti-Colorectal Cancer Compound Library

1,725 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1,725 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

HY-L074

Anti-Breast Cancer Compound Library

2,123 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 2,123 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Type

HY-149696

IR-Crizotinib

Dyes

IR-Crizotinib is a NF-κB-inducing kinase (NIK) inhibitor that crosses the blood-brain barrier and fluorescently localizes intracranial glioblastoma (GBM) in mice (IC₅₀=3.381 μM). IR-Crizotinib is conjugated from the near-infrared dye IR-786 and the NF-κB-inducing kinase (NIK) inhibitor Crizotinib. IR-Crizotinib can effectively inhibit the growth and invasion of glioma in vitro and in vivo and can be used in cancer research .

HY-B0185G

Lidocaine (GMP)

Lignocaine (GMP)

Fluorescent Dye

Lidocaine (GMP) is Lidocaine (HY-B0185) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .

Cat. No.	Product Name	Type

HY-W016412

Coenzyme Q0

2 Publications Verification

CoQ0

Enzyme Substrates

Coenzyme Q0 (CoQ0) is a potent, oral active ubiquinone compound can be derived from Antrodia cinnamomea. Coenzyme Q0 induces apoptosis and autophagy, suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of inflammation and redox imbalance. Coenzyme Q0 has anti-angiogenic activity through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling .

HY-P1956

Human serum albumin

1 Publications Verification

HSA

Native Proteins

Human serum albumin (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, NF-κB, and peroxynitrite (ONOO ⁻) in the vascular wall, contributing to the reduction of blood pressure .

HY-W042416

N,N-Dimethylacetamide 1 Publications Verification DMAc	Co-solvents
N,N-Dimethylacetamide (DMAc) is an organic solvent with blood-brain transmissibility and an FDA-approved drug excipient. N, N-dimethylacetamide exerts anti-inflammatory activity by inhibiting the *NF-κB* signaling pathway. N, N-dimethylacetamide can be used in studies of weight gain caused by a high-fat diet and neuroinflammation in Alzheimer's disease .

HY-125864

Fibrinogen (Bovine)

Native Proteins

Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .

HY-W001925

7-Methoxy-1-tetralone

Biochemical Assay Reagents

7-Methoxy-1-tetralone is a potent antitumor agent. 7-Methoxy-1-tetralone inhibits cancer cell proliferation and migration, and induces hepatocellular carcinoma cell (HCC) apoptosis. 7-Methoxy-1-tetralone decreased the protein levels of NF-κB, matrix metallopeptidase 2 (MMP2)/MMP9, and p-AKT. 7-Methoxy-1-tetralone showed antitumor activity in nude mice and had no effect on body weight and liver, spleen and organ index .

HY-D1056H

Lipopolysaccharides, from S. marcescens

LPS, from Serratia marcescens

Carbohydrates

Lipopolysaccharides, from S. marcescens, are lipopolysaccharide endotoxins that can activate pathogen-associated molecular patterns (PAMP) in the immune system and induce the secretion of exosomes by cells. Lipopolysaccharides can be extracted from the outer leaflet of the outer membrane of Gram-negative bacteria and consist of an O-specific antigen chain, a core oligosaccharide, and lipid A. Lipopolysaccharides, from S. marcescens, induce the activation of NF-κB in mouse cells through Toll-like receptor (TLR4)/MD-2. Lipopolysaccharides from S. marcescens can also induce apoptosis in host immune cellsS. marcescens .

HY-141582

Ceramide 3

N-Stearoyl phytosphingosine

Drug Delivery

C18 Phytoceramide (t18:0/18:0) (Cer(t18:0/18:0)) is a bioactive sphingolipid found in the stratum corneum of Saccharomyces cerevisiae, wheat grain, and mammalian epidermis. Cer(t18:0/18:0) consists of a phytosphingosine backbone amine linked to a C18 fatty acid chain. Cer(t18:0/18:0) has the function of regulating apoptosis, cell differentiation, proliferation of smooth muscle cells and inhibition of mitochondrial respiratory chain. It also suppresses the expression of allergic cytokines IL-4, TNF-α, and transcription factors c-Jun and NF-κB in histone-stimulated mouse skin tissue. Formulations containing cer(t18:0/18:0) have been used as skin protectants in cosmetics as they reduce water loss and prevent epidermal dehydration and irritation.

HY-NP018

Bovine fibrinogen (from plasma) FGA; FGA protein	Native Proteins
Bovine fibrinogen (from fibrinogen) is a native fibrinogen from bovine plasma. Bovine fibrinogen (from fibrinogen) can regulate the activation of *NF-KB* in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 .

HY-W042416R

N,N-Dimethylacetamide (Standard)

Co-solvents

N,N-Dimethylacetamide (Standard) is the analytical standard of N,N-Dimethylacetamide. This product is intended for research and analytical applications. N,N-Dimethylacetamide (DMAc) is an organic solvent with blood-brain transmissibility and an FDA-approved drug excipient. N, N-dimethylacetamide exerts anti-inflammatory activity by inhibiting the NF-κB signaling pathway. N, N-dimethylacetamide can be used in studies of weight gain caused by a high-fat diet and neuroinflammation in Alzheimer's disease .

HY-B0185G

Lidocaine (GMP)

Lignocaine (GMP)

Biochemical Assay Reagents

HY-P1956A

Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg)

HSA (Cell culture grade, Endotoxin<0.125 EU/mg)

Native Proteins

Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, iNOS, and peroxynitrite (ONOO ⁻) in the vascular wall, contributing to the reduction of blood pressure .

Cat. No.	Product Name	Target	Research Area

HY-P1832A

PTD-p65-P1 Peptide TFA 3 Publications Verification	NF-κB Apoptosis	Inflammation/Immunology Cancer
PTD-p65-P1 Peptide TFA is a potent, selective nuclear transcription factor *NF-κB* inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis .

HY-P0151

SN50 Maximum Cited Publications 35 Publications Verification	NF-κB	Inflammation/Immunology
SN50 is a cell permeable inhibitor of *NF-κB* translocation.

HY-P1860

TNF-α (31-45), human 5 Publications Verification	TNF Receptor NF-κB Apoptosis	Inflammation/Immunology Cancer
TNF-α (31-45), human is a potent *NF-kB* pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis .

HY-P1847A

IKKγ NBD Inhibitory Peptide TFA	NF-κB	Inflammation/Immunology
IKKγ NBD Inhibitory Peptide TFA is a highly specific inhibitor *NF-κB* inhibitor. IKKγ NBD Inhibitory Peptide TFA acts by disrupting the interaction between IKKγ/NEMO-binding domain (NBD) with IKKα and IKKβ, thus blocking TNF-α-induced NF-kB activation. IKKγ NBD Inhibitory Peptide TFA could significantly suppresses inflammation and ameliorate the cerebral ischemia-induced neurological deficits .

HY-P1832

PTD-p65-P1 Peptide	NF-κB Apoptosis	Inflammation/Immunology Cancer
PTD-p65-P1 Peptide is a potent, selective nuclear transcription factor *NF-κB* inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis .

HY-P1860A

TNF-α (31-45), human TFA	TNF Receptor NF-κB Apoptosis	Inflammation/Immunology
TNF-α (31-45), human TFA is a potent *NF-kB* pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis .

HY-P10469

NBD-2	NF-κB	Inflammation/Immunology Cancer
NBD-2 is an inhibitor of the NEMO-IKKα/β interaction in the *NF-κB* signaling pathway. NBD-2 specifically inhibits the typical *NF-κB* signaling pathway in vitro and in vivo, reducing the inflammatory response in lipopolysaccharide (LPS) induced acute lung injury (ALI). NBD-2 exhibits significant anti-inflammatory activity. NBD-2 can be used to study diseases related to *NF-κB* signaling pathway, including autoimmune diseases, cancer, etc .

HY-P10081

CTP-NBD	NF-κB	Inflammation/Immunology
CTP-NBD is a cell permeable specific NFκB peptide inhibitor. CTP-NBD could be used in colitis study

HY-P1847

IKKγ NBD Inhibitory Peptide	NF-κB	Cancer
IKKγ NBD Inhibitory Peptide is a highly specific inhibitor *NF-κB* inhibitor. IKKγ NBD Inhibitory Peptide acts by disrupting the interaction between IKKγ/NEMO-binding domain (NBD) with IKKα and IKKβ, thus blocking TNF-α-induced NF-kB activation. IKKγ NBD Inhibitory Peptide could significantly suppresses inflammation and ameliorate the cerebral ischemia-induced neurological deficits .

HY-138096

Z-LLF-CHO Z-Leu-Leu-Phe-CHO	Proteasome	Cancer
Z-LLF-CHO (Z-Leu-Leu-Phe-CHO) is a potent inhibitor of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex (K_i = 460 nM). Z-LLF-CHO is also a NF-κB nuclear translocation inhibitor .

HY-P1259

PR-39	Proteasome Bacterial	Inflammation/Immunology
PR-39, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric proteasome inhibitor. PR-39 reversibly binds to the α7 subunit of the proteasome and blocks degradation of NF-κB inhibitor IκBα by the ubiquitin-proteasome pathway. PR-39 stimulates angiogenesis, inhibits inflammatory responses and significant reduces myocardial infarct size in mice .

HY-P1259A

PR-39 TFA	Proteasome Bacterial	Inflammation/Immunology
PR-39 TFA, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric proteasome inhibitor. PR-39 TFAreversibly binds to the α7 subunit of the proteasome and blocks degradation of NF-κB inhibitor IκBα by the ubiquitin-proteasome pathway. PR-39 TFA stimulates angiogenesis, inhibits inflammatory responses and significant reduces myocardial infarct size in mice .

HY-P10399

KGYY15 Mouse KGYY15; KGYY15 peptide	TNF Receptor	Metabolic Disease
KGYY15 (Mouse KGYY15) is a CD40 targeting peptide, which weakly inhibits the CD40-CD40L interaction with IC₅₀ of more than 1mM. KGYY15 activates 33% NF-κB pathway at 100 μM .

HY-P10462

SAP15 Synthetic anti-inflammatory peptide 15	HDAC NF-κB	Inflammation/Immunology
SAP15 (Synthetic anti-inflammatory peptide 15) is a synthetic anti-inflammatory peptide consisting of 15 amino acids designed from human beta-defensin 3. SAP15 has the ability to penetrate cells and is able to induce downregulation of intracellular inflammation. SAP15 inhibits inflammation by inhibiting the phosphorylation of HDAC5 and thereby reducing the phosphorylation of NF-κB p65. In LPS-induced macrophages, SAP15 inhibits HDAC5 and NF-κB p65 phosphorylation. In addition, SAP15 treatment increased the expression of aggrecan and type II collagen and decreased the expression of osteocalcin in LPS-induced chondrocytes. SAP15 can be used in the study of inflammation regulation and anti-inflammatory therapy of biomaterials .

HY-P10350

PapRIV	NF-κB	Neurological Disease Inflammation/Immunology
PapRIV is an agonist of BV-2 microglial cells, capable of activating microglial cells through an *NF-κB*-dependent pathway. PapRIV induces the expression of pro-inflammatory cytokines such as IL-6 and TNFα and increases the production of reactive oxygen species (ROS). PapRIV can cross the blood-brain barrier .

HY-P1098

Ac2-26 4 Publications Verification	NF-κB	Inflammation/Immunology
Ac2-26, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue .

HY-P1098A

Ac2-26 TFA 4 Publications Verification	NF-κB	Inflammation/Immunology
Ac2-26 TFA, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue .

HY-100538A

DTP3 TFA 1 Publications Verification	DNA/RNA Synthesis JNK	Cancer
DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway .

HY-P3229

SN52 2 Publications Verification	NF-κB	Cancer
SN52 is a potent, competitive, and cell-permeable inhibitor of *NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB* heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research .

HY-P10349

Pap12-6	Bacterial	Infection Inflammation/Immunology
Pap12-6 is a 12-mer peptide derived from the antimicrobial peptide Papiliocin of yellow butterfly larva. Pap12-6 kills bacteria by penetrating and disrupting their membranes, exhibiting strong antibacterial activity. Pap12-6 exerts its anti-inflammatory effects through the TLR4-mediated *NF-κB* signaling pathway .

HY-P2036A

FSL-1 TFA 3 Publications Verification	Toll-like Receptor (TLR) MMP HSV Antibiotic	Infection
FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection . FSL-1 TFA induces MMP-9 production through TLR2 and *NF-κB/AP-1* signaling pathways in monocytic THP-1 cells .

HY-P1181

Pam2CSK4	Toll-like Receptor (TLR)	Inflammation/Immunology
Pam2CSK4, a lipopeptide, is a TLR6-independent TLR2 ligand and agonist. Pam2CSK4 promotes platelet aggregation, and increases platelet adhesion to collagen-coated surfaces in a TLR2/NF-κB/BTK-dependent manner. Pam2CSK4 also activates iNOS expression and NO production in mouse macrophages .

HY-P1181A

Pam2CSK4 TFA	Toll-like Receptor (TLR)	Inflammation/Immunology
Pam2CSK4 (TFA), a lipopeptide, is a TLR6-independent TLR2 ligand and agonist. Pam2CSK4 (TFA) promotes platelet aggregation, and increases platelet adhesion to collagen-coated surfaces in a TLR2/NF-κB/BTK-dependent manner. Pam2CSK4 (TFA) also activates iNOS expression and NO production in mouse macrophages .

HY-P1409

ADWX 1	Potassium Channel	Inflammation/Immunology
ADWX 1 is a new peptide inhibitor that is potent and selective for Kv1.3 with an IC₅₀ value of 1.89 pM. ADWX 1 inhibits Kv1.3 channel activity specifically to inhibit both the initial calcium signaling and NF-κB activation. ADWX 1 ameliorates the disease in rats of experimental autoimmune encephalomyelitis (EAE) models. ADWX 1 can be used to study T cell-mediated autoimmune diseases .

HY-P2114

IT9302	Peptides	Cancer
IT9302 is a synthetic IL-10 agonist with the activity of inducing tolerogenic dendritic cells. IT9302 is able to mimic multiple effects of IL-10, including downregulating the antigen presentation machinery and increasing the sensitivity of tumor cells to natural killer cell-mediated lysis. IT9302 can also hinder the response of human monocytes to differentiation factors and reduce the antigen presentation and co-stimulatory capacity of dendritic cells. Dendritic cells treated with IT9302 showed a weakened ability to stimulate T cell proliferation and interferon-γ production. IT9302 exerts its effects through mechanisms that are partially different from IL-10, involving STAT3 inactivation and regulation of the NF-κB intracellular pathway. IT9302-treated dendritic cells showed enhanced expression of membrane-bound TGF-β, associated with the effective induction of foxp3+ regulatory T cells .

Cat. No.	Product Name	Target	Research Area

HY-P9930

Evolocumab 2 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80245

	NF-KB p65 Antibody (YA267) 3 Publications Verification NF-κB p65 Antibody	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse
	NF-κB p65 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 65 kDa, targeting to NF-κB p65. It can be used for WB,ICC/IF,IHC-P,IP,FC assays with tag free, in the background of Human, Mouse.

HY-P80470

	Phospho-NF-κB p65 (Ser529) Antibody	WB, IP, FC, IHC-P	Human
	Phospho-NF-κB p65 (Ser529) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 60 kDa, targeting to Phospho-NF-κB p65(S529). It can be used for WB,IP,FC,IHC-P assays with tag free, in the background of Human.

HY-P81238

	Phospho-NF-κB p65 (Ser536) Antibody NF-kB p65 (phospho S536); p-NF-κB p65(Phospho-Ser536); RELA(phospho S536); NF kB P65; NF-kB p65; NFKBp65; NF-κBp65; p65 NF kappaB; p65 NFkB; NFKBp65; RELA; Transcription Factor p65; v rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B cells 3 (p65)); V Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A; v rel reticuloendotheliosis viral oncogene homolog A (avian); v-rel reticuloendotheliosis viral oncogene homolog A; p65NFKB; Avian reticuloendotheliosis viral (v rel) oncogene homolog A; MGC131774; NFKB 3; NFKB3; Nuclear Factor NF Kappa B p65 Subunit; Nuclear factor of kappa light polypeptide gene enhancer in B cells 3; Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B Cells; TF65_HUMAN. NFκB-p65; NFκB p65; NF κB-p65; NFκBp65	WB, IHC-P, FC	Human, Mouse, Rat
	Phospho-NF-κB p65 (Ser536) Antibody is a rabbit-derived non-conjugated IgG antibody, targeting Phospho-NF-κB p65 (Ser536), with a predicted molecular weight of 61 kDa. Phospho-NF-κB p65 (Ser536) Antibody can be used for WB, IHC-P, FC experiments in human, mouse, rat backgrounds.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-108039

Bezisterim HE 3286; NE-3107		Alkynes
Bezisterim (HE 3286; NE-3107) is a synthetic derivative of a natural anti-inflammatory steroid, β-AET. Bezisterim is an orally active partial *NF-κB* inhibitor. HE3286 reduces proinflammatory signals, including IL-6 and matrix metallopeptidase 3. Bezisterim freely penetrates the blood brain barrier in mice. Bezisterim can be used for the research of the ulcerative colitis, arthritis, experimental autoimmune encephalomyelitis . Bezisterim is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-N2041

Myristic acid 3 Publications Verification		Emulsifiers
Myristic acid is an orally active saturated 14-carbon fatty acid found in most animal and plant fats, especially milk fat coconut oil, palm oil and nutmeg oil. Myristic acid exerts anti-inflammatory activity through the *NF-κB* pathway. Myristic acid has antibacterial, anti-inflammatory and analgesic properties .

HY-150744A

ODN 24888 sodium		CpG ODNs
ODN 24888 sodium is an guanine-modified inhibitory oligonucleotides (INH-ODN), shows potent inhibition on TLR7/TLR9-mediated signaling. ODN 24888 sodium impairs IFN-α level and NF-κB activation, inhibits IL-6 release. ODN 24888 sodium involves in immune and inflammatory responses, can be used as a vaccine adjuvant .

HY-150744

ODN 24888		CpG ODNs
ODN 24888 is an guanine-modified inhibitory oligonucleotides (INH-ODN), shows potent inhibition on TLR7/TLR9-mediated signaling. ODN 24888 impairs IFN-α level and NF-κB activation, inhibits IL-6 release. ODN 24888 involves in immune and inflammatory responses, can be used as a vaccine adjuvant .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

NFκB

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products